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Long before synaptic loss occurs in Alzheimer’s disease significant harbingers of disease may be detected at the
functional level. Here we examined if synaptic long-term potentiation is selectively disrupted prior to extracellular
deposition of Aß in a very complete model of Alzheimer’s disease amyloidosis, the McGill-R-Thy1-APP transgenic
rat. Longitudinal studies in freely behaving animals revealed an age-dependent, relatively rapid-onset and persistent
inhibition of long-term potentiation without a change in baseline synaptic transmission in the CA1 area of the
hippocampus. Thus the ability of a standard 200 Hz conditioning protocol to induce significant NMDA receptor-dependent
short- and long-term potentiation was lost at about 3.5 months of age and this deficit persisted for at least another 2–3
months, when plaques start to appear. Consistent with in vitro evidence for a causal role of a selective reduction in NMDA
receptor-mediated synaptic currents, the deficit in synaptic plasticity in vivo was associated with a reduction in the synaptic
burst response to the conditioning stimulation and was overcome using stronger 400 Hz stimulation. Moreover,
intracerebroventricular treatment for 3 days with an N-terminally directed monoclonal anti- human Aß antibody,
McSA1, transiently reversed the impairment of synaptic plasticity. Similar brief treatment with the BACE1 inhibitor
LY2886721 or the γ-secretase inhibitor MRK-560 was found to have a comparable short-lived ameliorative effect
when tracked in individual rats. These findings provide strong evidence that endogenously generated human Aß
selectively disrupts the induction of long-term potentiation in a manner that enables potential therapeutic options to
be assessed longitudinally at the pre-plaque stage of Alzheimer’s disease amyloidosis.
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The detection and characterization of the prodromal
phase of Alzheimer’s disease (AD) has become a major
focus of research and potentially provides the opportun-
ity to intervene before clinical symptoms manifest [1].
Functional synaptic deficits mediated by pathogenic Aß
in vulnerable pathways may provide a means of develop-
ing much-needed therapeutic avenues [2].
There is compelling evidence that acute exogenous ap-
plication of soluble Aß aggregates, including oligomer-
containing media from AD brain extracts, strongly and
selectively disrupt hippocampal synaptic plasticity in
brain slices in vitro and in anaesthetized animals in vivo,
inhibiting the induction of long-term potentiation (LTP)
without affecting baseline synaptic transmission [2,3].
The onset of the synaptic plasticity deficit is very rapid,
occurring within minutes, but recently we found that
the inhibition of LTP induction can persist for more
than a week after injection of soluble AD brain Aß [4].
Research addressing the question as to whether or not
endogenously generated Aß affects LTP in a manner
similar to that caused by exogenous Aß has yielded
mixed findings [5,6]. Although LTP has been widely re-
ported to be impaired in many human amyloid precur-
sor protein (APP)-based transgenic (TG) mouse models
the selectivity of the deficit relative to reductions in
baseline synaptic transmission and the role of Aß remain
uncertain.
The investigation of non-murine animal models of AD
amyloidosis offers new means of exploring early disease
pathophysiology and thereby more rigorously testing the
potential translational value of animal models. TG rats,
in addition to introducing a species with many more
human-like characteristics such as postnatal brain devel-
opment and a more complex behavioural repertoire [7],
offer many distinct practical advantages over mice for
neurophysiological studies in vivo, particularly for long-
term recordings in longitudinal designs. In particular, a
novel, very complete, model of AD amyloidosis, the
McGill-R-Thy1-APP TG rat provides an excellent means
of exploring pre-plaque dysfunction [8-11] at the neuro-
physiological level.
Here we determined if, when and how synaptic plasticity
is disrupted during the pre-plaque stage of amyloidosis in
freely behaving and anaesthetized McGill-R-Thy1-APP
TG rats in vivo and in hippocampal slices in vitro. We re-
port a deficit in LTP induction that is associated with an
impairment in synaptic burst responsiveness and NMDA
receptor-mediated synaptic transmission. The synaptic
plasticity deficit, tracked in chronically implanted individ-
ual rats, develops quickly over a critical period and re-
mains stable for several months. Furthermore, brief
treatment with agents targeting Aß via three different
mechanisms rapidly, but transiently, restores the ability toinduce LTP. The practical advantages of the rat for longi-
tudinal neurophysiological investigation combined with
the stable pre-plaque Aß-mediated deficit in LTP induc-
tion offers new opportunities to assess potential early in-
terventions for AD in vivo.Materials and methods
Animals
All experiments were carried out in accordance with
guidelines under license from the Department of Health
and Children, Ireland (86/609/EEC) using methods simi-
lar to those described previously [12]. Prior to surgery
the animals were group-housed with free access to food
and water and a 12-h lights on/off cycle. Male TG rats
expressing human APP751 with Swedish and Indiana
mutations under the control of the murine Thy1.2 pro-
moter (McGill-R-Thy1-APP) [11] and their age-matched
wild type (WT) littermates were studied. Animals were
genotyped as outlined in Galeano et al. [8] and ages var-
ied from 3 to 6 months old. Some in-house outbred 2–6
month-old Wistar rats, the background strain for the
APP rats, were utilized in order to study the effects of
D-AP5 and MRK-560 in WT animals.In vivo surgery and electrophysiology
For non-recovery experiments the rats were anaesthe-
tized with urethane (1.5 g/kg, i.p.) and core body
temperature was maintained at 37.5 ± 0.5°C. For recov-
ery experiments the implantation procedure was com-
parable but carried out under anaesthesia using a
mixture of ketamine and xylazine (80 and 8 mg/kg, re-
spectively, i.p.) according to methods similar to those
described previously [13]. For the recovery experiments
the rats were allowed at least 14 days after surgery be-
fore recordings began. These rats were housed individu-
ally in their home cages post-surgery between recording
sessions.
Teflon-coated tungsten wire (external diameter 75 μm
bipolar or 112 μm monopolar) electrodes were positioned
in the stratum radiatum of area CA1. Screw electrodes lo-
cated over the contralateral cortex were used as reference
and earth. The stimulation and recording electrodes were
optimally located using a combination of physiological
and stereotactic indicators. Field excitatory postsynaptic
potentials (EPSPs) were recorded in the stratum radiatum
of the dorsal hippocampus in response to stimulation of
the ipsilateral Schaffer collateral-commissural pathway.
The recording site was located 3.8 mm posterior to
bregma and 2.5 mm lateral to midline, and the stimulating
site was located 4.6 mm posterior to bregma and 3.8 mm
lateral to midline. The final depths of the electrodes were
adjusted to optimize the electrically evoked EPSP and con-
firmed by post-mortem analysis.
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outer diameter, length 13 mm) was implanted above
the right lateral ventricle before the electrodes were im-
planted ipsilaterally. Injections were made via a
Hamilton syringe which was connected to the internal
cannula (28 gauge, 0.36 mm outer diameter). The in-
jector was removed 1 min post-injection and a stainless
steel plug was inserted. The position of the cannula was
verified post-mortem by investigating the spread of ink
dye after i.c.v. injection.
Test stimuli were delivered to the Schaffer-collateral/
commissural pathway every 30 s to evoke field EPSPs
that were 45-60% maximum amplitude. LTP was in-
duced using our standard 200 Hz or a stronger 400 Hz
high frequency stimulation (HFS) protocol. The 200 Hz
protocol consisted of a single series of 10 trains of 20
stimuli with an inter-train interval of 2 s. The stimula-
tion intensity was increased to 75% maximum for the
anaesthetized rats. A repeated 400 Hz protocol (3 sets of
10 trains of 20 pulses, inter-train interval of 2 s and
inter-set interval of 5 min), with the stimulation inten-
sity increased to 75% maximum, was used to investigate
NMDAR-independent LTP [14]. Paired-pulse facilitation
(PPF) was measured as second/first EPSP amplitude ra-
tio. The peak amplitude of the HFS-evoked field poten-
tial was expressed as a percentage the size of the test
field EPSP evoked by single pulse stimulation.
Recovery animal experiments were carried out in a
well-lit room. The recording compartment consisted of
the base of the home cage, including normal bedding
and food/water, but the sides were replaced with a trans-
lucent Perspex plastic box (27× 22× 30 cm) with an
open roof. The rats had access to food and water
throughout the whole recording session from the same
position as in the home cage. All animals were first ha-
bituated to the recording procedure over the post-
surgery recovery period.
Slice preparation and electrophysiology
Rats were anesthetised with isoflurane, the brain re-
moved and transverse hippocampal slices (350 μm) were
prepared in ice-cold artificial cerebro-spinal fluid (ACSF)
solution containing (in mM) 75 sucrose, 87 NaCl, 25
NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgCl2,
10 D-glucose, 1 ascorbic acid and 3 pyruvic acid. During
incubation and experiments slices were perfused with
ACSF containing (in mM) 125 NaCl, 25 NaHCO3, 2.5
KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgSO4, 25 D-glucose.
Slices were maintained at 33°C for 1 hr following dissec-
tion. All recordings were performed at physiological
temperature (32–34°C).
Whole-cell patch-clamp recordings were made from
CA1 pyramidal neurons, visualized using an upright
microscope (Olympus BX51 WI, Middlesex, UK) withinfra-red differential interference contrast optics (IR-
DIC). Patch pipettes were pulled from thick-walled boro-
silicate glass (World Precision Instruments, Sarasota,
FL) and had a resistance of 3–5 MΩ when filled with
intracellular solution containing (in mM) 130 KMeSO4,
10 KCl, 0.2 EGTA, 10 HEPES, 20 phosphocreatine, 2
Mg2ATP, 0.3 NaGTP, 5 QX-314, (pH 7.3, 290–
300 mOsm).
Unless otherwise stated, cells were voltage-clamped
at −60 mV. Electrically evoked excitatory postsynaptic
currents (EPSCs) were evoked at a test frequency of
0.033 Hz. Series resistance ranged from 5–17 MΩ and
was compensated by 50–80% (5 kHz bandwidth). HFS
consisted of 3 trains of 100 stimuli at 100 Hz, inter-
train interval of 10 sec, delivered in current clamp
mode. NMDAR-EPSCs were recorded in picrotoxin
(100 μM), 2, 3 dioxo-6-nitro-1, 2, 3, 4-tetrahydrobenzo
[f]quinoxaline-7-sulphonamide disodium salt (NBQX,
10 μM), CGP55845 (2 μM) and D-serine (20 μM) and
using an intracellular solution with CsMeSO4 substituted
for KMeSO4 and with the addition of QX-314 (5 μM) and
TEA (1 mM). Recordings were made using a Multiclamp
700B (Molecular Devices, Foster City, CA). Signals were
filtered at 5 kHz using a 4-pole Bessel filter and were digi-
tized at 10 kHz using a Digidata 1440 analogue-digital
interface (Molecular Devices).
Data were acquired and analyzed using PClamp 100,
Clampfit (Molecular Devices) and Strathclyde Electro-
physiology software (J. Dempster, University of Strathclyde,
Glasgow, UK).
Histology and immunohistochemistry
Rats were anaesthetized with an injection of ketamine
and xylazine (260 and 10 mg/kg, respectively, i.p.). After
transcardial perfusion with PBS pH 7.4 followed by 4%
PFA for 15 min, brains were removed and fixed over-
night in 4% PFA. Subsequently, the brains were stored in
PBS with 0.01% sodium azide until cutting at 4°C. Hun-
dred micrometer thick sections were cut on a vibratome
(VT1200, Leica, Germany) and immunohistochemical
staining was carried out. Free-floating sections were
blocked for 30 minutes in 4% normal goat, 4% BSA and
0.4% Triton-X in PBS. An antibody detecting the N-
terminus region of Aß in human APP (6E10) (mouse
monoclonal, 1:1000, Covance Research Products Inc.)
was applied to the solution and incubated overnight at
room temperature. A counterstain was performed using
the neuron-specific marker NeuN (1:1000, rabbit mono-
clonal, Merck Millipore). Sections were rinsed twice with
PBS before secondary labeling. Anti-mouse secondary
antibody AlexaFluor 488 and anti-rabbit secondary anti-
body AlexaFluor 647 (1:400, life technologies) were di-
luted in PBS and applied to the sections for two hours.
Slices were mounted on coverslips using fluorescent
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carried out on an inverted laser scanning microscope
(LSM700, Zeiss) with a 10×NA0.3 air objective and
20×NA0.8 air objective. AlexaFluor 488 and 647 were
excited at 488 nm and 633 nm respectively. The emis-
sion was detected with a SP 555 and LP650 filterset. Pic-
tures were acquired with a resolution of 0.893 μm/pixel
and 0.625 μm/pixel for zoom.
Western blotting
Proteins from frontal cortex were extracted to yield
fractions enriched in extracellular, intracellular, membrane-
associated, and insoluble proteins as previously described
[15]. Prior to biochemical analyses, all extracts were de-
pleted of endogenous immunoglobulins by incubation with
50 μL Protein-G Fast Flow sepharose beads (GE Health-
care) for 1 h at 4°C. Samples were centrifuged at 9300 × g
for 5 minutes to remove beads. Protein concentration was
determined using a BCA protein assay kit (Thermo Scien-
tific) according to the manufacturer’s instructions. 50 μg of
membrane-associated extracts were used to measure APP
expression. For immunoprecipitation experiments, 200 μg
extracellular-enriched or 100 μg membrane-associated pro-
tein extracts were incubated with 5 μg 6E10 (Covance) and
50 μL Protein-G-coated magnetic beads (Life Technolo-
gies) overnight at 4°C. The beads were then sequentially
washed for 20 min at 4°C with 1 mL buffer containing
50 mM Tris, 300 mM NaCl, 1 mM EDTA, and 0.1%
Triton-X100 followed by 1 mL buffer containing 50 mM
Tris, 150 mM NaCl, 1 mM EDTA, and 0.1% Triton-X100.
In all cases, proteins were denatured by heating at 95°C for
5 min under denaturing conditions, separated by SDS-
PAGE using 10-20% Tris-Tricine precast gels (Bio-Rad)
and electro-transferred onto 0.2 μm nitrocellulose mem-
branes at 0.4A for 3 h at 4°C. Membranes were boiled in
50 mL phosphate buffered saline by microwaving for 25 s,
followed by a 4 min wait, then again for 15 s and blocked
with 5% bovine serum albumin (Sigma-Aldrich) for 1 h at
room temperature. Membranes were probed with anti-
APPct (1:2500) (Invitrogen) followed by biotinylated don-
key anti-rabbit secondary (1:60,000) (Jackson Laboratories)
or probed with biotinylated 6E10 (1:2500). Membranes
were then incubated with NeutrAvidin-HRP (1:5000) (Life
Technologies). Signals were detected using West Pico
electro-chemiluminescence (ECL) (Thermo Scientific) and
bands were quantified using Optiquant software (Packard
Instruments).
Chemicals
McSA1 (Medimabs, Montreal, Canada) is a mouse mono-
clonal antibody that recognizes human Aß epitopes 1–12
[16]. The IgG control antibody 30B [17] was kindly pro-
vided by Dr Scott K. Dessain, Lankenau Institute of Med-
ical Research, PA, USA).The BACE1 (β–secretase 1) inhibitor LY2886721 (N-
[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]
thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxa-
mide) (Axon Medchem, Groningen, The Netherlands) and
γ-secretase inhibitor MRK-560 (N-[cis-4-[(4-Chlorophe-
nyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-
trifluoromethanesulfonamide) (Tocris, Bristol, UK)
were initially dissolved in dimethyl sulfoxide (DMSO,
Sigma, Dorset, UK). Final drug solutions were made up in
sterile 0.9% saline or distilled water (total volume i.c.v.
5 μl/injection/rat). The NMDAR antagonists (R)-3-(2-
carboxypiperazin-4-yl) propyl-1-phosphonic acid (CPP,
Ascent Scientific) and D-AP5 (Tocris) were initially dis-
solved in distilled water. Control injections consisted of
an equivalent amount of vehicle. CGP55845 was from
Tocris (Bristol, UK). All salts used were obtained from
Sigma as were picrotoxin and NBQX.
Data analysis
The magnitude of potentiation is expressed as the per-
centage of baseline during the initial 10- (in vitro) or 30-
(in vivo) min period, expressed as mean ± standard error
of the mean, unless otherwise stated. For statistical ana-
lysis, EPSP and EPSC amplitudes were grouped into 5-
(in vitro) or 10- (in vivo) min epochs. Standard one-way
and two-way ANOVA, with repeated measures as appro-
priate, were used to compare between multiple groups
followed by post hoc Bonferroni tests. Paired and un-
paired Student's t-tests were used for 2-group compari-
sons. A P < 0.05 was considered statistically significant.
Results
Biochemical characterization of the pre-plaque stage in
McGill-Thy1-APP-TG rats
Extracellular deposits of insoluble, fibrillar Aß only
begin to be detectable in restricted brain areas, such as
the subiculum, at ~7 months of age and mature dense
plaques only become widespread across the cortex and
hippocampus at ~12 months in McGill-Thy1-APP-TG
rats [10,11] (and data not shown). Hippocampal and
cortical neurons of 5 month-old pre-plaque TG animals
show strong intracellular staining with the antibody
6E10, a human specific antibody directed to the N-
terminus region of Aß in APP (Figure 1a). This staining
is coherent with prior reports using a variety of antibodies,
including some highly selective for Aß or oligomeric as-
semblies, that found evidence of the accumulation of non-
fibrillar Aß aggregates in these brain regions from as early
as 3 months of age [10,11]. Here we employed Western
blotting (WB) techniques in order to determine if we
could detect distinct Aß species in different brain fractions
of these APP-overexpressing rats at 3–4 months of age. In
the membrane-associated fraction of frontal cortex, the
total level of APP expression was approximately 1.4 fold
Figure 1 Biochemical characterization of pre-plaque McGill-Thy1-APP-TG rat brain. (a) Immunohistochemical staining with 6E10 (red), a
monoclonal antibody to the N-terminal region of Aß in APP, illustrates the lack of extracellular deposits in the hippocampus of a 5 month-old
TG rat. Sections were co-stained with the neuronal marker NeuN (green). Left hand panel shows low power view with NeuN staining. The
boxed areas are shown in high power in the right hand panels. Several cell bodies had overlapping intracellular staining (yellow in overlay,
Ovl) indicating intracellular reactivity in both hippocampal (CA1 area) and cortical neurons. The 6E10 staining that did not co-localize with
NeuN staining was caused by non-specific staining of blood vessels. Scale bars: overview 500 μm, insets 100 μm. (b,c) Characterization by
Western blotting using the antibody 6E10 of human APP breakdown products in membrane (b) and extracellular (c) fractions of cortical extracts from
3–4 month-old TG rats. (b) The membrane fraction contained Aß monomer (1-mer), C-terminal fragment-ß (CTF-ß) and full length APP (flAPP). It also
contained two other APP cleavage products (mACP 50–75 and mACP 37–50). (c) In contrast, the extracellular fraction contained mainly sAPPα with
trace amounts of Aß monomer and two other APP cleavage products (eACP 50–75 and eACP 10–15). The asterisks indicate non-specific bands.
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with an antibody that recognizes both human and ro-
dent C-terminal APP (data not shown). Using 6E10,
prominent bands corresponding to holo-APP along
with C-terminal fragment-ß and Aß monomers were
detected in the membrane fraction (Figure 1b). In con-
trast, in the extracellular-enriched cortical fraction from
TG rats, whereas sAPPα was prominent, only faint
amounts of Aß monomer were detected (Figure 1c). Thus,
the membrane fraction, which includes intracellular mem-
branes, contained considerably more Aß monomers than
the extracellular fraction. Although we used highly sensi-
tive techniques, that can readily detect SDS stable oligo-
meric aggregates in CSF and brain [18,19], we wereunable to definitively ascribe any of the strong WB bands
specifically to Aß oligomers in the 3–4 month-old TG rat
brain fractions. It seems likely, given the compelling evi-
dence for intracellular Aß aggregates at this age [10,11],
that, compared to other APP fragments in a similar mo-
lecular weight range, the concentration of oligomers was
relatively low in the membrane or extracellular fractions.
Age-dependent pre-plaque inhibition of LTP in the CA1
area of freely behaving rats
In order to determine if hippocampal synaptic plasticity
is disrupted before plaques are deposited in this TG rat
line we attempted to induce LTP of excitatory gluta-
matergic transmission at CA3-to-CA1 synapses in the
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animals and their WT littermates. Animals were im-
planted with chronic electrode assemblies and acclima-
tized to the recording protocol in their home cage,
which had been modified to allow wire attachment. We
used our standard 200 Hz HFS protocol, which triggers
an NMDA receptor-dependent LTP of synaptic trans-
mission at these synapses [14,20,21]. In 3 month-old TG
rats the application of HFS induced robust LTP that
persisted for at least 3 h (138.8 ± 7.4% mean ± S.E.M.
pre-HFS baseline, n = 8; P < 0.05 compared with base-
line, two-way repeated measures ANOVA with post
hoc Bonferroni test) and that was similar in magnitude
to that induced in age-matched WT littermates (139.3 ±
7.6%, n = 5; P > 0.05 compared with TG; P < 0.05 com-
pared with baseline) (Figure 2a). In marked contrast, LTP
was strongly impaired in 4 month-old TG rats. Thus, at
this age the 200 Hz conditioning protocol failed to induceFigure 2 Pre-plaque disruption of hippocampal LTP induction in
freely behaving TG rats in vivo (a,b). In freely behaving chronically
implanted rats, LTP at CA3-to-CA1 synapses in the stratum radiatum was
strongly impaired in 4 but not 3 month-old McGill-Thy1-APP-TG rats. (a)
At 3 months of age application of a standard 200 Hz conditioning
stimulation protocol (standard HFS, arrow) induced robust LTP that
persisted for at least 3 h in both WT and TG rats. (b) In contrast, at
4 months of age, whereas the same conditioning stimulation triggered
robust LTP in WT rats, the protocol only triggered a weak, non-
significant, STP in TG rats. Time-course graphs are shown in the left
hand panels with summary statistics for STP (first 10 min post-HFS) and
LTP (last 10 min post-HFS) shown in the right hand panels. Insets show
representative EPSP traces at the times indicated. Calibration bars:
Vertical, 1.0 mV; horizontal, 10 ms. Values are the mean ± S.E.M. %
pre-HFS baseline EPSP amplitude. *P < 0.05 compared with
WT littermates.LTP (102.2 ± 2.6%, n = 14; P > 0.05 compared with base-
line; P < 0.05 compared with 145.0 ± 6.7% in 4 month-old
WT littermates, n = 6) (Figure 2b). A similar significant re-
duction in the initial magnitude of potentiation (short-
term potentiation, STP), as measured in the first 10 min
after HFS, was present at 4 months of age in TG rats
(111.6 ± 6.2%; P < 0.05 compared with 141.0 ± 2.2% in
WT; P > 0.05 compared with baseline) (Figure 2b).
This age-dependent deficit in the ability to induce STP
and LTP in TG rats appeared to be relatively selective
since baseline AMPA receptor-mediated synaptic excit-
ability, as measured by input–output properties, and
PPF, measured using a 40 ms inter-pulse interval (IPI),
were not significantly different from WT controls at ei-
ther 3 or 4 months of age (Table 1).
Increasing the conditioning stimulation strength
overcomes the inhibition of LTP
Next we reasoned that if the inhibition of LTP in the
TG rats was caused by an increase in the threshold for
LTP induction, it should be possible to overcome the
inhibition of LTP with a stronger conditioning stimula-
tion protocol. For these studies we tested 5–6 month-
old TG rats, an age when the standard HFS still failed
to induce LTP (102.3 ± 1.3%, n = 5; P > 0.05 compared
with baseline; P < 0.05 compared with 140.4 ± 3% in 5–
6 month-old WT littermates, n = 5) (Figure 3a). The
stronger conditioning protocol consisted of three sets
of high-intensity, 400 Hz trains of stimuli, which trig-
gers a large LTP in WT rats in vivo that is both NMDA
receptor- and voltage-gated Ca2+ channel-dependent
[14]. To our surprise, stimulation with this strong HFS
protocol in pre-plaque, 5–6 month-old, TG rats in-
duced robust LTP (153.5 ± 9.2% at 3 h post-HFS, n = 14;
P < 0.05 compared with baseline), comparable in magni-
tude with that elicited in WT littermates (168.3 ±
11.8%, n = 6; P < 0.05 compared with baseline; P > 0.05
compared with TG group) (Figure 3b). Similar results
were found for STP (148.8 ± 13.9 and 164.6 ± 17.8% in
TG and WT, respectively) (Figure 3b).
Consistent with our previous findings in WT rats [14],
the high-intensity 400 Hz protocol induced an LTP in
the TG rats that was NMDA-receptor-dependent, being
strongly blocked by pretreatment with the NMDA recep-
tor antagonist CPP (10 mg/kg, i.p.) (118.4 ± 5.2%, n = 5;
P < 0.05 compared with baseline; P < 0.05 compared with
TG in the absence of CPP, data not shown).
Inhibition of LTP and reduced synaptic burst responses in
anaesthetized TG rats
In order to determine if the deficit in LTP in the TG rats
was relatively independent of behaviour, the ability to in-
duce LTP with the standard 200 Hz conditioning stimu-
lation protocol was evaluated in acutely anaesthetized
Table 1 Baseline synaptic efficacy and paired pulse facilitation (PPF) were not significantly disrupted in freely
behaving pre-plaque 3–6 month-old McGill-Thy1-APP TG rats
Age (month) WT n TG n
Baseline EPSP 3 1.5 ± 0.2 (5) 1.5 ± 0.6 (7)
(50% maximum amplitude, mV) 4 1.2 ± 0.2 (5) 1.2 ± 0.1 (6)
6 1.0 ± 0.3 (5) 0.9 ± 0.3 (6)
Stimulation intensity 3 9.2 ± 0.3 (5) 9.4 ± 0.2 (7)
(50% maximum, mA) 4 9.8 ± 0.2 (5) 9.9 ± 0.3 (6)
6 10.8 ± 0.6 (5) 10.7 ± 0.3 (6)
Stimulation intensity 3 13.3 ± 0.3 (5) 12.9 ± 0.4 (7)
(maximum, mA) 4 12.2 ± 0.4 (5) 12.0 ± 0.6 (6)
6 12.8 ± 0.6 (5) 13.1 ± 0.6 (6)
PPF (ratio) 3 1.6 ± 0.1 (5) 1.6 ± 0.1 (7)
40 ms IPI 4 1.6 ± 0.1 (5) 1.6 ± 0.1 (6)
6 1.5 ± 0.1 (5) 1.5 ± 0.1 (6)
Figure 3 Increasing the strength of the conditioning stimulation
protocol overcame the inhibition of LTP in pre-plaque freely
behaving TG rats. (a) At 5–6 months of age the standard 200 Hz
conditioning stimulation (arrow) triggered robust LTP in WT rats but
failed to induce significant STP or LTP in TG rats. (b) Repeated high-
intensity 400 Hz tetanization (strong HFS, large arrow head) in 5–6
month-old animals induced similar magnitude LTP in TG and WT rats.
Time-course graphs are shown in the left hand panels with summary
statistics for STP (first 10 min post-HFS) and LTP (last 10 min post-HFS)
shown in the right hand panels. Insets show representative EPSP traces
at the times indicated. Calibration bars: Vertical, 1.0 mV; horizontal,
10 ms. Values are the mean ± S.E.M. % pre-HFS baseline EPSP
amplitude. *P < 0.05 compared with WT littermates.
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was on the cusp of the age when the deficit in freely be-
having animals was detected (see also longitudinal data
in a later section of the Results section). Both STP and
LTP were strongly impaired in the TG rats at this age.
Thus HFS triggered a small STP and no significant LTP
of excitatory synaptic transmission in these TG rats
(116.7 ± 4.8 and 101.0 ± 3.6%, at 10 min and 3 h post-
HFS, respectively, n = 10; P < 0.05 and P > 0.05 compared
with baseline, respectively; P < 0.05 compared with
132.5 ± 2.7 and 131.3 ± 9.0%, respectively in WT litter-
mates, n = 5) (Figure 4a).
There was no significant correlation between the mag-
nitude of potentiation at either 10 min or 3 h post-HFS
in the TG rats and the amount of Aß monomer in the
membrane fraction of the cortical extracts measured by
WB (Figure 1b and data not shown).
Similar to freely behaving animals, the deficit in the
ability to induce LTP in anaesthetized TG rats appeared
to be relatively selective since measures of baseline syn-
aptic excitability or PPF (at 20, 40 and 100 ms IPI) were
statistically indistinguishable between groups (Table 2).
Although short-term plasticity, as measured by PPF,
was not noticeably affected, the response to burst stimula-
tion during the conditioning HFS protocol was attenuated
in the TG rats. Thus the magnitude of the peak amplitude
of the burst field potential response during the HFS was
significantly smaller in TG rats (144.5 ± 8.8% single test
EPSP amplitude, n = 14, compared with 178.5 ± 9.0%, n =
5, in WT littermates) (Figure 4b). Interestingly, there was
a strong positive correlation between the magnitude of
peak burst response to the HFS and the level of HFS-
induced STP in the TG group (r = 0.62; P < 0.05). Since
both synaptically generated bursting activity [22,23] and
Figure 4 LTP inhibition and reduced synaptic burst responses
in anaesthetized TG rats. (a) Both STP and LTP were strongly
impaired in 3.5-4 month-old urethane anesthetized TG rats compared
with age-matched WT rats. Standard 200 Hz conditioning stimulation
(arrow) induced robust LTP in the controls but not in the TG rats.
Time-course graphs are shown in the left hand panel. Insets show
representative EPSP traces at the times indicated. Vertical, 1.0 mV;
horizontal, 10 ms. (b) The peak amplitude of the HFS-evoked field
potential (expressed as a % of the pre-HFS baseline EPSP amplitude)
was significantly reduced in TG rats compared with WT littermates.
Insets show representative EPSPs triggered by a single test pulse (i,
left hand trace) and the average of 10 trains of 200 Hz burst of 20
stimuli (ii, right hand trace) in WT and TG rats. (c) The NMDA receptor
antagonist D-AP5 reduced the peak amplitude of the HFS-evoked field
potential in WT animals. Injection i.c.v. with 100 nmol D-AP5 10 min
prior to HFS significantly reduced the burst response. Calibration bars:
Vertical, 1.0 mV; horizontal, 20 ms. Values are the mean ± S.E.M. %
pre-HFS baseline EPSP amplitude. Summary statistics are shown in
the right hand panels. *P < 0.05 compared with WT littermates.
Table 2 Baseline synaptic efficacy and paired pulse
facilitation (PPF) were not significantly disrupted in
anaesthetized pre-plaque 3.5-4 month-old McGill-Thy1-
APP TG rats
WT (n = 5) TG (n = 16)
Baseline EPSP 2.0 ± 0.2 1.9 ± 0.1
(50% maximum amplitude, mV)
Stimulation intensity (mA)
50% max 6.2 ± 0.2 6.3 ± 0.2
75% max 8.0 ± 0.4 8.2 ± 0.2
100% max 13.4 ± 0.8 13.5 ± 0.3
PPF (ratio)
20 ms IPI 1.6 ± 0.1 1.5 ± 0.05
40 ms IPI 1.7 ± 0.05 1.6 ± 0.1
100 ms IPI 1.5 ± 0.05 1.5 ± 0.05
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we tested the ability of the NMDA receptor antagonist D-
AP5 to inhibit the burst response to HFS in WT animals
under our recording conditions. Pretreatment with D-AP5
(100 nmol, i.c.v.) significantly reduced the peak burst re-
sponse from 188.5 ± 3.2% to 170.2 ± 2.9% (n = 7; P < 0.05)
(Figure 4c). These data are consistent with a deficit in LTPinduction via an impairment of excitatory synaptic activa-
tion during the induction protocol.
Inhibition of LTP and reduced NMDA receptor-mediated
synaptic transmission in vitro
As described above, in vivo field potential measures of
baseline excitatory synaptic transmission, which are
AMPA receptor-mediated, were not significantly affected
in TG rats at an age when NMDA receptor-dependent
STP and LTP of that transmission was strongly impaired.
Because the burst response to the conditioning stimula-
tion in anaesthetized rats was reduced in a manner con-
sistent with a decrease in NMDA receptor-mediated
synaptic transmission, we were interested in examining
glutamatergic mechanisms in TG rats at this age in detail.
Therefore we carried out in vitro experiments that en-
abled us to directly measure AMPA and NMDA receptor-
mediated components of synaptic transmission using
intracellular recording methods. We monitored both elec-
trically evoked and spontaneous currents at CA3-to-CA1
synapses from individual pyramidal cells using whole-cell
patch clamp techniques in hippocampal slices.
First, we assessed the ability of a standard set of 1 s
trains at 100 Hz to induce NMDA receptor-dependent
LTP [25,26]. Consistent with the in vivo field EPSP
findings described above, both STP and LTP of electric-
ally evoked AMPA receptor-mediated synaptic currents
were strongly impaired in slices from 3.5-4 month-old
TG rats. Whereas the 100 Hz conditioning protocol
triggered robust STP and LTP in WT littermate con-
trols (132.1 ± 1.5 and 140.6 ± 4.3% at 5 and 60 min
post-HFS, respectively; P < 0.05 compared with base-
line), this was not the case in TG rats (112.3 ± 1.5 and
96.1 ± 1.6%, respectively; P < 0.05 compared with the
WT group) (Figure 5a). Similar to the in vivo findings,
the LTP deficit in vitro was not associated with a
Table 3 Intrinsic properties, spontaneous and miniature
EPSCs, and paired pulse facilitation (PPF) of AMPA
receptor-mediated evoked EPSCs were not significantly
disrupted in hippocampal slices from pre-plaque 3.5-5
month-old McGill-Thy1-APP TG rats
WT TG
Intrinsic Properties (n = 7, 9 cells) (n = 6, 14 cells)
(3.5-5 months)
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transmission, determined over the full input–output
range (n = 16 WT and 21 TG rats) (Figure 5b), or PPF
of these currents (Table 3) in TG animals. Moreover,
background AMPA receptor-mediated transmission
measured in the absence (spontaneous EPSCs) or pres-
ence of the Na+ channel blocker tetrodotoxin (mini-
ature EPSCs), was not noticeably different between TGFigure 5 LTP inhibition and reduced NMDA receptor-mediated
synaptic transmission in TG rat hippocampal slices in vitro. (a) LTP
was strongly impaired in hippocampal slices from 3.5-4 month-old TG
rats. The magnitude of potentiation at 5 (STP) and 60 (LTP) min after
application of a 100 Hz conditioning stimulation protocol (arrow) was
significantly reduced in TG animals compared with their WT littermates.
(b,c) Whereas baseline AMPA receptor-mediated synaptic currents
were not affected, NMDA receptor-mediated synaptic currents
were reduced. (b) The input/output relationship for AMPA
receptor-mediated EPSCs was very similar in WT and TG rats. (c) In
contrast, NMDA receptor-mediated EPSCs were significantly smaller
in TG rats. Insets show representative EPSC traces. Calibration bars:
Vertical, 100 pA; horizontal, 10 ms. Values are the mean ± S.E.M. %
pre-HFS baseline EPSC amplitude. Summary statistics are shown in
the right hand panels. *P < 0.05 compared with WT littermates.
Resting membrane −61.6 ± 2.1 −63.8 ± 1.7
potential (mV)
τ membrane (ms) 14.3 ± 1.0 15.1 ± 1.0
Sag Ratio 0.9 ± 0.01 0.9 ± 0.01
sEPSCs (n = 5, 6 cells) (n = 9, 9 cells)
(4–4.5 months)
Amplitude (pA) −14.3 ± 1.1 −12.8 ± 1.0
Frequency (Hz) 3.5 ± 1.5 2.4 ± 0.6
mEPSCs (n = 5, 6 cells) (n = 9, 9 cells)
(4–4.5 months)
Amplitude (pA) −12.1 ± 1.1 −11.3 ± 1.1
Frequency (Hz) 1.2 ± 0.4 1.1 ± 0.3
AMPA EPSCs (n = 15, 23 cells) (n = 25, 44 cells)
(3.5-5 months)
PPF (ratio) 50 ms IPI 1.4 ± 0.1 1.5 ± 0.04and WT rats. Neither the amplitude nor the frequency
of these EPSCs was significantly different between
groups (Table 3). Thus, the impairment in LTP in TG
rats is unlikely to be caused by any change in spontan-
eous or evoked synaptic transmission mediated through
AMPA receptors.
In order to assess electrically evoked NMDA-receptor
mediated component of synaptic transmission we depolar-
ized the membrane to −40 mV and used a stimulation in-
tensity that evoked an AMPA receptor-mediated current
of approximately 50% maximum. TG rats had significantly
smaller amplitude NMDA receptor-mediated synaptic
currents (−102.1 ± 18.6 pA, n = 7; 9 cells; P < 0.05 com-
pared with −166.4 ± 28.7 pA in WT group, n = 7; 9 cells,
one-tailed t test when grouped by animals, two-tailed
when grouped by cells) (Figure 5c). These data are consist-
ent with the in vivo finding that the burst response to the
conditioning stimulation was reduced, presumably as a re-
sult of decreased NMDA receptor-mediated synaptic
transmission under depolarizing conditions.
We also measured some intrinsic neurophysiological
properties of CA1 pyramidal neurons under current
clamp conditions. We found no difference between WT
and TG rats (Table 3), indicating that the deficit in
NMDA receptor-mediated transmission or LTP was not
caused by disruption of these intrinsic properties.
Figure 6 Longitudinal studies reveal age-dependent relatively
rapid-onset and persistent LTP impairment in individual TG rats.
(a,b) The age of onset and time course of the development of the
deficit in LTP was assessed using a longitudinal study design. (a) We
evaluated the ability of the 200 Hz HFS protocol to induce potentiation
at weekly intervals in individual animals between 3 and 4 months of
age. The top pair of panels shows time-course graphs of LTP induced
by repeated weekly application of the HFS protocol in two WT control
animals. The HFS triggered similar magnitude LTP each time during
the repeated recording sessions. In contrast, the ability to induce STP
and LTP was impaired at slightly different ages in individual TG rats as
shown in the bottom pair of panels. Arrow heads: HFS application
Horizontal lines: 100% baseline EPSP amplitude Calibration bars:
Vertical, 50% change in EPSP amplitude; Horizontal, 30 min. (b)
Summary grouped data for the magnitude of STP and LTP tracked
repeatedly in the same WT and TG rats at fortnightly intervals between
3 and 6 months of age. The ability of the HFS protocol to induce LTP
was lost between 3 and 4 months of age and the loss persisted for the
remaining 2-month recording period. Values in (b) are the mean + S.E.
M. EPSP amplitude at 3 h after the HFS. *P < 0.05 compared with WT.
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tion in TG rats followed longitudinally
Having found that LTP was impaired in 4, but not 3,
month-old freely behaving TG rats in the cross-sectional
study, we went on to investigate the time course of the
deficit in individual animals longitudinally. We were able
to study LTP at weekly intervals because the LTP in-
duced by our standard HFS in freely behaving WT rats
reverted back to pre-HFS baseline levels within 7 days
(data not shown) and LTP was of similar magnitude
from week-to-week in WT animals (Figure 6a). The pat-
tern of the time course of the decline in the ability to in-
duce STP and LTP between 3 and 4 months of age
varied slightly from rat to rat in the TG group. In the
majority of animals the decline appeared to be relatively
fast, both STP and LTP apparently disappearing over a
1–2 week period (Figure 6a). In some animals the de-
cline took several weeks, with LTP being more suscep-
tible than STP. In order to determine if the disruption of
STP and LTP was stable in individual animals over the
months prior to plaque formation we tested them fort-
nightly up to the age of 6 months. Unlike their WT litter-
mates, from 4 to 6 months of age repeated application of
the HFS protocol in individual TG rats consistently failed
to trigger significant STP (100.8 ± 7.2 and 99.0 ± 4.6%, n =
6, at 4 and 6 months, respectively; P > 0.05 compared with
baseline) or LTP (108.4 ± 2.2 and 104.8 ± 2.9%, n = 6, at 4
and 6 months, respectively; P > 0.05 compared with base-
line) (Figure 6b).
Rapid-onset transient reversal of LTP deficit by agents
targeting Aß in TG rats followed longitudinally
Finally, given the maintained inhibition of the ability to in-
duce LTP in TG rats from 4–6 months of age, the ques-
tion arises as to whether or not the deficit is reversible
with therapeutically relevant interventions that are known
to target Aß in the brain. In view of the power of the lon-
gitudinal design we were particularly interested in profil-
ing the onset and duration of any reversal of the LTP
deficit. Because currently available agents can affect non-
Aß targets we chose to evaluate the efficacy of three differ-
ent approaches that differentially affect other components
of APP processing: an anti-Aß antibody, a BACE1 inhibi-
tor and a γ-secretase inhibitor.
We studied the ability to induce LTP 2 h after the last
injection (five i.c.v. injections over three days) with these
agents. First we assessed McSA1, which is an N-terminally
directed monoclonal antibody that recognizes all forms of
human Aß [11,16]. TG (4.5 month-old) animals were
tracked longitudinally before, during and after receiving
the anti-Aß antibody or an IgG isotype control antibody
(10 μg per injection). Whereas standard HFS failed to in-
duce LTP prior to McSA1 treatment, the same condition-
ing protocol triggered LTP in the same TG animals wheninjected with the antibody. Thus McSA1 restored the abil-
ity to induce LTP in TG rats (142.7 ± 7.2%, n = 5; P < 0.05
compared with 104.8 ± 3.2% in animals injected with the
control antibody, n = 6; P < 0.05 compared with pre-
injection) (Figure 7a). Indeed the magnitude of STP and
LTP appeared similar to that induced in age-matched WT
rats (see Figure 6b). However, the antibody-mediated re-
versal of the synaptic plasticity deficit was transient since
two weeks after ceasing McSA1 treatment HFS again
Figure 7 An anti-Aß antibody rapidly reverses the pre-plaque
LTP deficit (a,b). Three-day treatment with the anti-Aß monoclonal
antibody McSA1 transiently restored the ability to induce LTP in
4.5 month-old TG rats. (a) In animals treated with McSA1 (5 X
10 μg injections i.c.v.), but not with an isotype control IgG antibody,
HFS triggered robust STP and LTP that was stable for at least 3 h. Left
hand panel shows the time course of synaptic plasticity. Summary bar
chart of STP and LTP in left hand panel. *P < 0.05 compared with
isotype control IgG antibody. Insets show representative EPSP
traces at the times indicated. Calibration bars: Vertical, 1.0 mV; horizontal,
10 ms. (b) The recovery from the impairment in synaptic plasticity lasted
for less than two weeks in the McSA1-treated group. The same HFS
protocol applied either just before (pre) or two weeks after (post)
the injections of McSA1 (n = 5) failed to induce either STP or LTP.
Data for individual animals are shown in the first two panels and
summarized statistically in the bar charts. *P < 0.05 compared with pre.
Values are the mean ± S.E.M. % pre-HFS baseline EPSP amplitude at
10 min (STP) or 3 h (LTP).
Figure 8 A BACE1 inhibitor reverses the pre-plaque LTP deficit
(a,b). Three-day treatment with the BACE1 inhibitor LY2886721
transiently restored the ability to induce LTP in 4.5 month-old TG
rats. (a) In animals treated with LY2886721 (5 X 0.2 nmol injections
i.c.v.), but not with vehicle, HFS triggered robust STP and LTP that
was stable for at least 3 h. Left hand panel shows the time course
of synaptic plasticity. Summary bar chart of STP and LTP in left
hand panel. *P < 0.05 compared with vehicle. Insets show representative
EPSP traces at the times indicated. Calibration bars: Vertical, 1.0 mV;
horizontal, 10 ms. (b) The recovery from the impairment in synaptic
plasticity lasted for less than a week in the LY2886721-treated group.
The same HFS protocol applied either just before (pre) or one week
after (post) the injections of LY2886721 (n = 6) failed to induce either
STP or LTP. Data for individual animals are shown in the first two
panels and summarized statistically in the bar charts. *P < 0.05
compared with pre. Values are the mean ± S.E.M. % pre-HFS
baseline EPSP amplitude at 10 min (STP) or 3 h (LTP).
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compared with baseline) or LTP in the same TG rats
(104.7 ± 2.1%; P > 0.05 compared with baseline)
(Figure 7b).
Next we tested the BACE1 inhibitor LY2886721, which
is known to reduce cerebral Aß load rapidly [27]. Using
a similar protocol to that used when investigating the ef-
fect of McSA1, LY2886721 (0.2 nmol per injection i.c.v.)
yielded very similar findings in 4.5 month-old TG rats.
Thus the pre-treatment LTP deficit in individual animals
was reversed by the BACE1 inhibitor (140.3 ± 16.1%,
n = 6; P < 0.05 compared with 100.9 ± 3.1% in vehicle-
injected TG animals, n = 6; p < 0.05 compared with pre-
injection) (Figure 8a). The STP deficit was similarly
restored by LY2886721 in TG rats (155.1 ± 7.5%; P < 0.05
compared with 102.0 ± 2.3% in vehicle-injected TG rats)(Figure 8a). This dose of LY2886721 did not affect LTP
in WT control animals (136.8 ± 6.2%, n = 3, data not
shown; similar in magnitude to age-matched WT ani-
mals in the absence of LY2886721, Figure 6b). Again,
the reversal of the synaptic plasticity impairment was
transient, lasting less than 1 week (Figure 8b).
Finally, treatment with the γ-secretase inhibitor
MRK-560 (five i.c.v. injections over 3 days, each injec-
tion containing 0.19 nmol) reversed the LTP deficit in
5 month-old animals (124.8 ± 8.0%, n = 7; P < 0.05 com-
pared with 101.1 ± 3.0% in the same animals before
starting the drug treatment) (Figure 9). The vehicle was
the same as that used in the study with LY2886721 and
likewise this dose of MRK-560 did not affect LTP in
WT rats (133.8 ± 5.8%, n = 5; P < 0.05 compared with
123.2 ± 3.7% pre-drug treatment, data not shown).
Figure 9 A γ-secretase inhibitor reverses the pre-plaque LTP deficit
(a,b). Three-day treatment with the γ-secretase inhibitor MRK-560
transiently restored the ability to induce LTP in 5 month-old TG
rats. (a) In animals treated with MRK-560 (5 X 0.19 nmol injections
i.c.v.) HFS triggered robust STP and LTP that was stable for at least
3 h. Left hand panel shows the time course of synaptic plasticity.
Summary bar chart of STP and LTP in left hand panel. *P < 0.05
compared with pretreatment levels of potentiation in the same animals
(pre). Insets show representative EPSP traces at the times indicated.
Calibration bars: Vertical, 1.0 mV; horizontal, 10 ms. (b) Data for individual
animals pre-, during and one week post-treatment with MRK-560 are
shown in the two panels. *P < 0.05 compared with pre. Values are the
mean ± S.E.M. % pre-HFS baseline EPSP amplitude at 10 min (STP) or
3 h (LTP).
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The McGill-R-Thy1-APP TG rat, a very comprehensive
model of AD amyloidosis [11], became resistant to the
induction of synaptic LTP in the dorsal hippocampus
many months prior to the deposition of fibrillar Aß in
extracellular plaques. The increase in LTP threshold was
accompanied by reductions in (a) STP, (b) the synaptic
response to burst stimulation and (c) the NMDA
receptor-mediated component of excitatory synaptic
transmission. In contrast, there was no detectable
change in baseline AMPA receptor-mediated synaptic
transmission in pre-plaque animals. Longitudinal studies
in freely behaving rats revealed that the LTP deficit was
relatively rapid in onset and stable over many months.
Importantly, brief treatment with an anti-Aß antibody, a
BACE1 inhibitor or a γ-secretase inhibitor transiently re-
versed the impairment in LTP induction. Overall, these
findings strongly indicate that endogenous non-fibrillar
human Aß triggers a reversible disruption of synapticplasticity by impairing synaptic NMDA receptor func-
tion very early in the pathogenesis of AD.
In the present study we monitored synaptic transmis-
sion and plasticity of that transmission in cross-sectional
studies of pre-plaque TG rats and longitudinally in indi-
vidual animals over several months. We found that syn-
aptic LTP was strongly disrupted at approximately
4 months of age both in vivo and in vitro: in vitro in hip-
pocampal slices and in vivo in both acutely anaesthetized
and chronically implanted freely behaving TG animals.
Importantly, the inhibition of LTP could be overcome by
increasing the strength of the conditioning protocol, in-
dicating that the threshold for LTP induction and not
LTP maintenance or expression was primarily disrupted
at the earliest, pre-plaque stage of amyloidosis. More-
over, the deficit in LTP was relatively selective, baseline
synaptic transmission and paired pulse facilitation being
unaffected, as measured by field potentials in vivo and
spontaneous, miniature and evoked AMPA receptor-
mediated synaptic currents in slices. A notable feature of
the pattern of inhibition of LTP was the accompanying
profound and consistent reduction in STP in all three
preparations. Moreover, the relatively rapid onset of the
disruption of both LTP and STP between 3 and 4 months
of age went hand-in-hand in the longitudinal studies.
How the synaptic plasticity deficits described here relate
to the known behavioural impairments in hippocampus-
dependent tasks of this TG line from the age of 3 months
[8,10,11] is uncertain. Whereas learning on a Y-maze was
impeded in the TG rats at 6 but not 3 months of age, defi-
cits in spatial reference memory and novel object place
learning were detected at 3 months [8,10]. It will be inter-
esting to determine if milder conditioning stimulation
protocols than those used here reveal an LTP deficit at
3 months of age.
The impairment of STP led us to suspect that the in-
hibition of LTP was related to an early event in the
process of induction. Because sufficient NMDA receptor
activation is critical in initiating both STP and LTP at
CA3-to-CA1 synapses with our induction protocols in
WT animals [21,24,25] we were encouraged to probe
NMDA receptor function in the TG rats in vivo by
examining the synaptic burst response during condition-
ing stimulation [22] and in vitro by measuring pharma-
cologically isolated NMDA receptor-mediated synaptic
currents recorded intracellularly from pyramidal cells.
Consistent with a reduction in NMDA receptor function
mediating the block of STP and LTP, we found a re-
duced synaptic burst response in anaesthetized TG rats
that correlated negatively with the magnitude of STP
and that was mimicked in WT rats by the application of
an NMDA receptor antagonist. Moreover, an ~40% de-
crease in the NMDA receptor-mediated component of
synaptic transmission as observed in slices from TG rats
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LTP [25,26,28-30]. A reduction in NMDA receptor func-
tion at the level of the synapse is therefore likely to me-
diate the inhibition of both STP and LTP in the TG rats
at 4 months of age.
There is a dearth of information regarding in vivo pre-
plaque neurophysiology in APP TG mice [31-33], pos-
sibly because of the well-known technical difficulties in
carrying out such experiments in the mouse. Previous
in vitro reports in pre-plaque APP TG mice have found
inconsistent changes in baseline transmission and LTP,
the variability being due, at least partly, to technical as-
pects of using the hippocampal slice preparation [6,34].
So far, the only other APP TG rat model that appears to
have been investigated has been reported to have pre-
plaque deficits in synaptic LTP in the CA1 area when
studied in vitro [35]. In a number of TG mouse studies
that found deficits in LTP the possible involvement of
reduced NMDA receptor-mediated function has been
supported [6,36-39]. Thus, for example, in pre-plaque
APPLON mice impaired NMDA, and to a lesser extent
AMPA, receptor-mediated field potentials were found
associated with reduced STP and LTP in the CA1 area
[37]. Indeed Cissé et al. [36] posited a critical role for
loss of the receptor tyrosine kinase EphB2 in mediating
selective reduction in NMDA receptor-mediated synap-
tic currents in dentate granule cells from pre-plaque
APPSWE/IND mice. Genetic restoration of EphB2 not only
enhanced NMDA receptor-mediated transmission but
also rescued STP and LTP deficits at medial perforant
path to granule cell synapses. Furthermore the loss of
EphB2 function was triggered by Aß oligomer binding
with high affinity to this receptor, which was subse-
quently internalized. Aß may also downregulate NMDA
receptor function via other high affinity binding sites in-
cluding α7-nicotinic acetylcholine receptors [40,41] and
cellular prion protein [42,43]. Somewhat paradoxically,
Aß oligomers may reduce synaptic NMDA receptor-
mediated synaptic transmission by initially enhancing
extrasynaptic currents through NMDA receptors, in par-
ticular those containing GluN2B subunits [28,44-46].
Interestingly, we have preliminary evidence that the re-
duction in NMDA receptor-mediated synaptic transmis-
sion in the TG rats was largely due to a decrease in the
contribution of GluN2B subunit-containing receptors to
the synaptic currents (Harney, S. et al. unpublished).
Consistent with previous research reporting elevated
Aß concentration in soluble tris-buffered saline (TBS)
brain extracts from pre-plaque TG rats [10] we detected
Aß monomer in the membrane and to a lesser extent
the extracellular fraction of cortical extracts. However,
the levels of SDS stable monomer did not correlate with
the magnitude of potentiation in these pre-plaque rats.
Although we were unable to definitively detect Aßoligomers using WBs with the antibody 6E10, possibly
because of the denaturing conditions in the present
study [47,48], evidence supporting the presence of oligo-
meric intraneuronal Aß has already been provided using
super resolution microscopy with the monoclonal anti-
body Nu1 that selectively recognizes oligomeric con-
formation [10,11]. Indeed, in pilot experiments we found
evidence on tricine gels of hippocampal TBS extracts of
a negative correlation between the density of a 6E10 re-
active band with a molecular weight of ~12-15 kDa,
which corresponds to the C-terminal fragment-ß and
possibly Aß trimers [11], and LTP in freely behaving 5–6
month-old TG rats (Wilson, E. N. et al. unpublished).
Future studies should revisit this issue using more sensi-
tive and specific assays of soluble Aß oligomers, includ-
ing ELISAs with a suitable antibody detection system
[49]. Rather than rely on correlational analysis, we
assessed the role of Aß using three different interven-
tions that share the ability to target Aß in different ways
using a combined longitudinal and cross-sectional de-
sign. We found that a relatively brief 3-day treatment
with these agents transiently reversed the inhibition of
LTP in pre-plaque rats. Thus the N-terminus-directed
monoclonal antibody McSA1, that directly binds human
Aß, and the selective BACE1 inhibitor LY2886721, and
γ-secretase inhibitor MRK-560, that both potently in-
hibit Aß production, all reversed the LTP deficit. These
findings are consistent with previous results in cross-
sectional studies of pre-plaque TG mice that reported
relatively rapid reversal of cognitive impairment by anti-
Aß antibodies [50,51], BACE1 inhibitors [52] and γ-
secretase inhibitors [53]. Furthermore MRK-560 rapidly
restored LTP deficits in pre-plaque TG mouse hippo-
campus ex vivo [34]. Although these interventions separ-
ately can affect different non-Aß targets they share the
ability to inhibit Aß. Whether or not intracellular or
extracellular Aß is the main culprit remains to be deter-
mined. Overall, our findings leave little doubt that Aß
mediates the impairment in synaptic plasticity in the
pre-plaque TG rat.
More sensitive and specific assays may be necessary in
order to fully delineate which Aß species is contributing
to the deficit in LTP. The relatively rapid on and off rates
for the ameliorative effects of treatment with either the
anti-Aß antibody or the secretase inhibitors strongly indi-
cates that at this early stage of amyloidosis the synaptic
plasticity impairment caused by Aß does not appear to
rely on some very slowly developing or irreversible
process [4]. Our finding that once an inhibition of LTP
was present in a given TG rat the ability to trigger LTP
remained compromised for several months prior to plaque
deposition will allow future studies to evaluate the persist-
ence of any beneficial effects of continued chronic treat-
ment with these and other potential therapeutic avenues.
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